Millions of heart failure patients could be saved thanks to a new stem cell therapy being tested in Britain. Researchers revealed a breakthrough treatment that cuts out the need for operations by revitalising damaged tissue using cells harvested from a patient’s own blood.
Widecells Group (LON:WDC), are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.